122 results about "Type antigen" patented technology

The present disclosure provides lipid nanoparticle compositions comprising a nucleic acid encoding an RSV antigenic polypeptide. The invention also provides novel antigenic RSV-F polypeptides as well as nucleic acids encoding the antigenic RSV-F polypeptides.

The invention relates to the technical field of vaccines, and discloses a preparation method and application of an anti-tumor vaccine based on an autoantigen and a synthetic antigen. The anti-tumor vaccine comprises a tumor autoantigen and a synthetic antigen, wherein the tumor autoantigen is extracted from a tumor cell membrane, a tumor cell lysate, a tumor cell secretion, an exosome antigen or an antigen released by a tumor microenvironment; the synthetic antigen is selected from at least one of a tumor associated antigen, a tumor specific antigen, a personalized neoantigen, a pathogen antigen, a biotoxin, a biomolecule antigen and coding nucleic acid of a peptide type antigen in the antigens; the coding nucleic acid is DNA or mRNA. The vaccine molecule composed of the tumor autoantigen and the synthetic antigen is easy to prepare, has a strong anti-tumor immune effect and good biological safety, solves the problems that the traditional tumor autoantigen has no specific precise target spot and the synthetic antigen is single in immunogen, and has a wide application prospect.

The invention provides compositions and methods for treating diseases associated with expression of CD19, e.g., by administering a recombinant T cell comprising the CD19 CAR as described herein, in combination with one or more B-cell inhibitors, e.g., inhibitors of one or more of CD10, CD20, CD22, CD34, CD123, FLT-3, ROR1, CD79b, CD179b, or CD79a. The disclosure additionally features novel antigen binding domains and CAR molecules directed to CD20 and CD22, and uses, e.g., as monotherapies or in combination therapies. The invention also provides kits and compositions described herein.

The invention relates to the technical field of vaccines, in particular to an activity detection method of an HPV (human papilloma virus) trivalent therapeutic vaccine. The method comprises the following steps: inoculating and infecting BEAS-2B cells by adopting constructed HPV16 / 18 / 52 type E6 / E7 antigen-loaded non-replicating type 5 adenovirus, culturing, extracting total protein, sequentially performing SDS-PAGE (Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis), western blot detection, immunoreaction and developing imaging, and detecting the fusion protein; the transfection complex number MOI of the constructed adenovirus is 15-25, and the convergence degree of BEAS-2B cells is greater than 80%; the membrane transfer current of the western blot method is 220-280 mA, and the time is 50-80 minutes. The method avoids the problem of inaccurate detection results caused by obvious difference of biological activities in different animal species, has good accuracy, stability and durability, is simple in steps and low in cost, and can be effectively popularized and used.

The invention belongs to the technical field of biological medicines, and particularly relates to an MAF vaccine as well as a preparation method and application thereof. In order to develop a nasal spray type vaccine capable of effectively preventing and treating fibrotic interstitial lung diseases and avoiding risk increase caused by local inflammatory reaction, the invention adopts two modes of taking a synthesized MAF protein as a model antigen, encapsulating the MAF protein by using a TLR7 adjuvant to form a peptide fragment vaccine or constructing an MAF adenovirus vaccine based on an adenovirus vector. Two vaccines based on the MAF target spot are successfully constructed. Animal experiment results prove that the two vaccines based on the MAF target spot have treatment and prevention effects on bleomycin-induced mouse pulmonary fibrosis models during nasal dripping immunization, and also have good safety in vivo. A good candidate vaccine is provided for future fibrotic disease prevention and treatment vaccine transformation research and clinical experiment development.

The present invention relates to bi-specific antigen binding molecules with specificity for both receptor tyrosine kinase-like orphan receptor 1 (ROR1) and epidermal growth factor receptor (EGFR) and associated fusion proteins and conjugates. In a further aspect, the present invention relates to conjugated immunoglobulin-like shark variable novel antigen receptors (VNARs).

The present application provides enhanced APCs for use in the treatment of HPV-associated cancers. The enhanced APC is capable of activating T cells in an HLA-agnostic manner and is derived from an input APC in which at least one nucleic acid encoding an HPV antigen has been delivered within the cell. In some aspects, the enhanced APC is administered in combination with an immune checkpoint inhibitor, such as an antagonist of PD-1 / PD-L1 and / or an antagonist of CTLA-4.

The invention relates to the field of biological detection, in particular to a broad-spectrum specific antibody and application thereof. The invention provides a monoclonal antibody of human immunodeficiency virus P24 protein. Three CDR regions of a heavy chain of the monoclonal antibody respectively have amino acid sequences shown as SEQ ID NO: 3, 4 and 5; the three CDR regions of the light chain of the gene respectively have amino acid sequences as shown in SEQ ID NO: 7, 8 and 9. A recombinant human immunodeficiency virus P24 protein is used as an immunogen, a monoclonal antibody capable of simultaneously detecting HIV-1 and HIV-2 core proteins P24 is successfully prepared through different multi-type antigen sequential immunization strategies, an epitope interval of the monoclonal antibody is determined through a recombinant P24 fragment, and a foundation is laid for establishing a detection kit with higher sensitivity.

The present invention discloses an antibody against HPV16 and / or HPV18 type E2 protein, an antibody conjugate and their applications, which relate to the field of medical biotechnology. The antibody comprises the heavy chain complementarity determining regions in the heavy chain variable region shown in SEQ ID NO: 1, and the light chain complementarity determining regions in the light chain variable region shown in SEQ ID NO: 2. After testing, the kit developed based on this monoclonal antibody has the advantages of high detection sensitivity for HPV16 and / or HPV18 type E2 antigen, good specificity, high intermediate precision, high accuracy, consistent linear range of the standard curve, rapid detection and strong tolerance. It can be used for quality control in the production process of recombinant human HPV16 and / or HPV18 type E2 antigen, can efficiently and accurately quantify the antigen content in the vaccine, and monitor the vaccine quality.

According to the kit for detecting the helicobacter pylori CagA subtype and the application of the kit, 3E67 and 5T68 monoclonal antibodies are prepared by using CagA dominant immune epitopes, and the monoclonal antibodies are used in a homogeneous chemiluminescence system for the first time to prepare an antigen for detecting the helicobacter pylori CagA subtype. A murine antibody is prepared through immunization of dominant epitopes of helicobacter pylori CagA protein, an antibody pair with good specificity and strong binding force is obtained through an in-vitro screening pairing strategy, and amino acid sequences of a heavy chain variable region and a light chain variable region of the antibody pair are obtained through sequencing. Products for detecting the helicobacter pylori-related CagA antigen are developed on the basis of a chemiluminescence platform, an enzyme-linked immunosorbent assay platform and an immune layer system platform, and the kit has the advantages of high sensitivity, good specificity and rapid detection.

The present invention generally relates to improved protease-activatable antigen-binding molecules. The protease-activatable antigen-binding molecules contain an anti-idiotypic binding portion that reversibly masks the CD3 antigen-binding portion of the molecule. Furthermore, the present invention relates to polynucleotides encoding such protease-activatable T cell binding molecules, as well as vectors and host cells containing such polynucleotides. The present invention further relates to methods for producing the protease-activatable T cell binding molecules of the present invention and methods for using the protease-activatable T cell binding molecules, for example, in the treatment of diseases.

Provided is a low mass antigen detecting device for quickly and conveniently detecting various types of antigens. In a low mass antigen detecting device for detecting a low mass antigen through a sensor, the sensor includes a piezo-electric substrate, a sensing layer coupled to one surface of the piezo electric substrate and comprising at least one antigen-BSA, an input IDT electrode disposed at one side of the piezo-electric substrate to apply an input frequency provided as a sweep frequency, and an output IDT electrode disposed at the other side of the piezo-electric substrate to output an output frequency.

The invention relates to a multi-metal element nano-aluminum adjuvant and a preparation method and application thereof, the nano-aluminum adjuvant is a nano-particle containing an aluminum element and at least one metal element selected from magnesium, zinc and calcium, the nano-particle has a layered crystal structure, and the particle size is distributed in a range of 20-2000 nm. The difunctional nano-aluminum adjuvant has the beneficial effects that the difunctional nano-aluminum adjuvant is simple and convenient in preparation method, definite in component and uniform in particle size, the particle size of the particles can be manually regulated and controlled, and the difunctional nano-aluminum adjuvant can directly promote antigen presenting cells to be mature and activated and carry out MHC-I or II type antigen presentation.

The present application relates to the field of medicine, and specifically discloses a nine-valent human papillomavirus vaccine and its application. The nine-valent human papillomavirus vaccine includes truncated L1-VLP antigens of HPV6, 11, 16, 18, 31, 33, 45, 52, and 58, and an aluminum hydroxide adjuvant. The antigen components in the nine-valent HPV vaccine provided by the present invention are all derived from the main capsid protein L1 of HPV and are truncated. The truncated L1 protein expressed by the Escherichia coli system increases the yield of the L1 protein and reduces the production cost of the vaccine. The present application optimizes the particle size of each type of VLP antigen and the particle size of the aluminum hydroxide adjuvant, and controls the ratio of each type of VLP antigen and the aluminum hydroxide adjuvant, so that the obtained nine-valent HPV vaccine induces a high level of immune response, especially showing obvious effects in clinical practice, which is better than the effects of related vaccines currently on the market.

The application provides a PLA2R monoclonal antibody and an ELISA kit comprising the antibody. Specifically, the application provides a monoclonal antibody which specifically binds to PLA2R, wherein the antibody only binds to non-reduced PLA2R antigen with a conformational epitope, does not bind to reduced PLA2R antigen, and does not bind to another antigen THSD7A of primary membranous nephropathy. An ELISA kit prepared based on the antibody can more efficiently and accurately detect primary membranous nephropathy than existing commercial kits.

The present invention provides protected tetrasaccharides, their process of preparation and their use as common scaffold precursors in the synthesis of oligosaccharides representing segments of the O-antigens from diverse S. flexneri serotypes, comprising for example SF2a, SF3a, SF2b, SF1b, SFX and / or SFY.

The application provides novel peptide epitope tags and recombinant polynucleotide, polypeptides, vectors, cells and compositions comprising the tags. The application also provides novel designs for synthetic antigen receptors (SARs), novel antigen binding domains, novel SAR constructs and novel methods for manufacturing of cell therapy products. These novel methods and compositions have broad uses in cellular therapy.

The application provides an anti-Norovirus GII genotype VP1 antigen monoclonal antibody and an application thereof. The anti-Norovirus GII genotype VP1 antigen monoclonal antibody comprises a heavy chain variable region and a light chain variable region, the heavy chain variable region comprises a heavy chain CDR3 shown in SEQ ID NO. 3, and the light chain variable region comprises a light chain CDR3 shown in SEQ ID NO. 6. The monoclonal antibody is a rabbit-derived monoclonal antibody, the monoclonal antibody has good specificity and high affinity, and solves the problem of a mouse-derived monoclonal antibody in actual application. The anti-Norovirus GII genotype VP1 antigen monoclonal antibody has important application value in the preparation of a product for detecting Norovirus.

Provided is a novel antigen detection method capable of detecting an antigen, as a substance to be detected, by using a signal transmission line for transmitting a high-frequency signal. This antigen detection method for detecting an antigen in a sample comprises: a step in which a sample, containing an antigen reacted with both a primary antibody for fixing the antigen to a carrier and a secondary antibody labelled with magnetic particles, is produced; a step in which the sample is placed close to or in contact with a probe in which a signal transmission line is formed; a step in which a DC magnetic field in a direction along the signal transmission line is applied to the sample by a magnetic field application means; a step in which a high-frequency signal is supplied to the signal transmission line by a signal measurement instrument electrically connected to the signal transmission line; a step in which a signal being transmitted along the signal transmission line in a state in which the DC magnetic field is being applied is measured by the signal measurement instrument over a predetermined frequency band; and a step in which the antigen is detected by an arithmetic processing means on the basis of a signal corresponding to the resonance frequency of ferromagnetic resonance observed in the predetermined frequency band.

The invention discloses an FUT2 high-expression cell strain as well as application and a method of the FUT2 high-expression cell strain in vaccine quality control, and belongs to the technical field of vaccines. The technical problem to be solved is that a simple and easy-to-operate cell model is lacked in the prior art, and the cell model is used for evaluating the effectiveness of NoV vaccines on the cellular level. According to the key points of the technical scheme, the FUT2 high-expression cell strain is provided, the cell strain is an HEK 293T cell strain (HEK 293T-FUT2-EGFP) with EGFP fluorescence for overexpressing human alpha 1, 2-fucosyltransferase 2 (FUT2), and the cell strain stably expresses H, Lewis b and Lewis y type HBGA antigens; meanwhile, an alternative neutralization experiment of the cell level of the norovirus vaccine based on the cell strain is developed, a basis is provided for interaction research of the norovirus and host cells, and the cell strain has high practical application value.

Disclosed is a chemical synthesis method for Pseudomonas aeruginosa O5 serotype O-antigen oligosaccharide, which belongs to the field of chemical synthesis. In the disclosure, O-antigen trisaccharide is constructed with a D-glucuronic acid building block and a D-fucosamine building block, where the stereoselective synthesis of a 1,2-α-cis-glycosidic bond of D-fucosamine depends on remote acyl participation and reagent regulation, and synthesis of two types of 1,2-β-trans-glycosidic bonds of 2,3-diaminomannuronic acids is achieved via SN2 nucleophilic substitution of azido at position C2; and via selective assembly of protecting groups, orthogonal modification of modifying groups, and regulation of the reactivity of glycosyl donors and acceptors, multifunctional modified O-antigen target trisaccharide is successfully prepared. According to the method in the disclosure, the raw materials are cheap and easily available, and the preparation method is simple and easy to repeat. Therefore, the method has a very good application prospect in developing vaccines against P. aeruginosa.

The invention provides an O-type foot-and-mouth disease nanoparticle antigen NP-OVPn as well as a preparation method and application thereof. The NP-OVPn provided by the invention is obtained by the following steps: after intracellular self-assembled O-type foot-and-mouth disease nanoparticle antigen NP-OVPn-T is subjected to TEV enzyme cleavage, removing T fusion-promoting tag protein through nickel affinity chromatography purification, and enabling antigen epitopes to be fully exposed on the surface of nanoparticle carrier protein NP. According to the FMDV O-type NP-OVPn nanoparticle antigen, three structural proteins of FMDV O-type VP1, VP2 and VP3 are displayed at the same time in the form of nanoparticles, the FMDV O-type NP-OVPn nanoparticle antigen can well and uniformly react with antibodies generated after immunization or infection of three animals including pigs, cattle and sheep, and the problem that the source of the FMDV O-type antigen is limited in FMDV clinical diagnosis is solved. The invention also provides a vaccine developed on the basis of the NP-OVPn nanoparticle antigen, and an FMDV O-type LB-ELISA antibody detection kit. The kit can be simultaneously used for quantitative detection of FMDV O-type specific antibodies from three different animals, namely pigs, cows and sheep, and has the advantages of high sensitivity, good specificity and high accuracy.

The invention discloses a GAGE7 recombinant antigen as well as a preparation method and application thereof, and belongs to the technical field of biological detection. The amino acid sequence of the GAGE7 recombinant antigen is shown as SEQ ID NO.1. Through verification, compared with a wild type GAGE7 antigen, the detection sensitivity of the GAGE7 recombinant antigen is remarkably improved, and meanwhile, the performance of the GAGE7 recombinant antigen is obviously superior to that of a commercially available GAGE7 recombinant antigen. Therefore, the GAGE7 recombinant antigen has a good application prospect in the field of early detection of lung cancer.

Disclosed herein is a genetically modified mouse whose genome comprises a transgene encoding a Miltenberger blood group antigen subtype III (Mi.II antigen). According to embodiments of the present disclosure, the Mi.III antigen comprises the amino acid sequence of SEQ ID NO: 1. Also disclosed herein are a method of producing the genetically modified mouse, and uses of the genetically modified mouse in selecting a drug candidate for treating hypertension.

The invention relates to the technical field of computational biology, artificial intelligence and drug discovery, in particular to a Foke-Planck equation-based antibody complementary determining region generation method and device.The method comprises the steps of defining a forward stochastic differential process, constructing a neural network-based generation model, and then obtaining an antibody complementary determining region based on de-noising prediction; an implicit fractional field of the generative model is parsed and a Foke-Planck equation (FPE) residual is calculated to train at least one parameter of the generative model for generating the CDR by minimizing a composite loss function containing regularization terms associated with the FPE residual. Therefore, the problems that a correlation generation model objective function only pays attention to local gradients, neglects global physical coherence and excessively depends on a public database with limited data volume and biased distribution, so that chemical unreasonable or energy unstable conformations are generated, and a novel effective combination mode is difficult to generate due to performance reduction when facing novel antigens are solved; the clinical application value is limited.

The invention discloses a preparation method and application of a Taq DNA polymerase monoclonal antibody based on structural domain analysis, which are specifically different from a traditional method using full-length Taq polymerase as an immunogen (the method generally cannot generate a functional blocking antibody due to a hidden epitope which is difficult to approach). According to the invention, by adopting a structure-oriented and domain-specific strategy, the exposure of epitopes related to active sites is remarkably enhanced, and a novel antigen Taq-P protein is developed. Based on the antigen, a high-specificity inhibitory monoclonal antibody is prepared, and the antibody is expected to become a core component of a high-performance hot start PCR reagent. According to the invention, a novel and generalizable mode is established for the development of a core diagnostic reagent, a key raw material is provided for gene detection and molecular diagnosis, and a valuable methodological framework is contributed to the development of propulsor engineering and biotechnology reagents.

Disclosed are a chemical synthesis method for Vibrio cholerae serotype O100 O-antigen oligosaccharide, and a use, belonging to the technical field of chemistry. The present invention uses three monosaccharide building blocks and five kinds of carboxylic acid derivative, and under the effects of solvent, temperature and neighboring group participation, through orthogonal protection, selective assembly and amide coupling, five Vibrio cholerae serotype O100 O-antigen oligosaccharide fragments are synthesized. Using the synthesized oligosaccharide fragments, combined with NMR analysis and carbohydrate chip technology, the absolute configuration and immunological function of the 3,5-dihydroxyhexanoyl group in the O-antigen trisaccharide are clarified, providing a theoretical basis for further structure-activity research and minimal antigen epitope screening. The present invention has promising applications in the synthesis of Vibrio cholerae glycoconjugate vaccines and the development of new drugs.

The invention provides a hybridoma cell strain secreting an IgG1 type monoclonal antibody resisting human N-type blood group antigen, the hybridoma cell strain is named as N1C8 and preserved in the China Center for Type Culture Collection on August 7, 2025, and the preservation number is CCTCC NO: C2025231. The invention further provides a monoclonal antibody secreted by the hybridoma cell strain secreting the IgG1 type monoclonal antibody resisting the human N-type blood group antigen and application of the monoclonal antibody. The cell strain is used for preparing a monoclonal antibody for resisting the human N-type blood group antigen, salt and protein are added into the antibody to develop a human N-type blood group antigen detection reagent, and the human N-type blood group antigen detection reagent can be applied to detection of the human N-type blood group antigen, so that a human N-type blood group antigen detection method is more scientific and perfect.

The invention relates to a duck infectious serositis pentavalent inactivated vaccine as well as a preparation method and application thereof. The vaccine is prepared from a duck infectious serositis type 1 antigen, a duck infectious serositis type 2 antigen, a duck infectious serositis type 6 antigen, a duck infectious serositis type 7 antigen and a duck infectious serositis type 10 antigen. The preparation method comprises the following steps: S1, strain screening; step S2, strain culture; step S3, carrying out inactivation treatment; step S4, bacterial liquid mixing; and S5, emulsifying the adjuvant. The duck infectious serositis pentavalent inactivated vaccine has the advantages of prominent broad spectrum, excellent immune effect and high industrial feasibility, can cover more than 90% of epidemic strains, solves the problem of incomplete prevention of the existing vaccine, has protection rates of more than or equal to 90% on the attack of five serotype virulent poison, adopts a fermentation tank for amplification culture in a culture process, has stable bacterial liquid proliferation efficiency, and is suitable for large-scale production. Emulsifying process parameters are clear and suitable for large-scale production.

The present invention provides methods and systems that identify novel antigens that bind to a particular T cell receptor and also validate the immunogenicity of the potential antigens to activate the TCR. The methods allow for development of an exhaustively profile of on-target and off-target reactivity of novel antigens.